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In the present issue of Arthritis Research & Th  erapy, de 
Brouwer and colleagues review the literature pertaining 
to experimental studies targeting acute-phase reactivity 
in the stress-response systems of patients with rheuma-
toid arthritis (RA) and systemic lupus erythematosus 
(SLE) [1]. Th  e authors included only studies employing 
experimental stressors (psychosocial, cognitive, exercise, 
and sensory/pain induction) to evaluate physiological 
responses at three levels – the autonomic nervous system 
(ANS), the hypothalamic–pituitary–adrenal (HPA) axis, 
and the immune system – in patients with RA and SLE.
Sixteen studies were identiﬁ  ed [1]. Th  e authors found 
inconsistent results regarding experimentally induced 
stress and the ANS and HPA axis baseline levels and 
reactivity, but found some evidence for alterations in 
immune functioning in patients compared with controls. 
Th   ey noted that the most consistent ﬁ  nding in response 
to experimentally induced stress was an increase in the 
number of natural killer cells, but this may not be 
surprising because natural killer cell traﬃ   cking is very 
sensitive to stress hormones such as catecholamines. Th  e 
authors note, however, that many of the studies possessed 
methodo  logical problems of their own. Most studies 
were under  powered (that is, small sample sizes) and 
some failed to control for potential confounders such as 
medication use, age, sex, psychiatric comorbidity, stress 
coping/appraisal and abuse history. In patients with 
rheumatologic illness, the presence of depression and a 
history of abuse are relatively common and have been 
associated with altera  tions in the stress-response and 
immune systems [2,3].
Th  e results from the present review of the eﬀ  ects of 
stress in RA and SLE suggest that the ﬁ  ndings in these 
disorders are congruent with a broader literature includ  ing 
both animal models and clinical studies of other rheumatic 
disorders. A number of diﬀ  erent types of stress have been 
shown to induce arthritis in animal models [4]; however, 
such a relationship in humans is more tenuous.
Most studies are limited by the use of cross-sectional 
designs and the pitfalls associated with self-report retro-
spective data, but their ﬁ  ndings are still of interest. For 
example, a study of Vietnam combat veterans with 
current post-traumatic stress disorder (n = 2,490) found 
that they were at increased risk for autoimmune diseases 
(16.7%, 95% conﬁ  dence interval = 7.9 to 29.3%) compared 
with those without post-traumatic stress disorder (6.1%, 
P <0.05) [5]. In that study, the combination of several 
stress-related conditions seemed to further increase this 
risk, with 8.1% of these male veterans with both post-
traumatic stress disorder and comorbid depression, 
anxiety or other signiﬁ  cant psychopathology reporting a 
diagnosis of RA [5].
Other studies have contemplated a role for early life 
stressors in increasing vulnerability to autoimmune 
disease. One recent study found that individuals report-
ing two or more traumatic childhood events were at a 
100% increased risk for rheumatic diseases compared 
with those reporting no childhood trauma [6]. Further, a 
multitude of studies have described relationships 
between psychological stress and poor outcomes in both 
RA and SLE including disease ﬂ  ares. Th  e mechanisms 
presumed to underlie these associations include stress-
related changes in functioning of the autonomic, 
neuroendocrine and/or immune systems.
Abstract
Rheumatology patients frequently note the occurrence 
of stressful or traumatic life events prior to the onset 
of their illness and/or a relationship between stress 
and disease fl  ares. For our patients, identifying causal 
events could represent an eff  ort to give meaning to 
a chronic and often disabling disease, while noting a 
link between stress and fl  ares may proff  er a sense of 
control. Whatever purpose the report of stress as an 
etiological or maintaining factor may serve, the science 
exploring a causal relationship between stress and 
autoimmune disease onset and course is expanding. 
Moreover, stress can also induce symptoms such as 
pain via nonimmunological mechanisms.
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symptoms, especially pain, in other nonautoimmune 
rheu  matic conditions such as ﬁ  bromyalgia might also be 
instructive in elucidating the role of stress in symptom 
expression. From a vast array of experimental studies it is 
reasonable to conclude that a variety of stressors may 
cause pain, that pain may cause stress, and, more 
importantly, that a simple unidirectional relationship 
between changes in stress-response function and pain 
and other symptoms probably does not exist. Imaging 
studies of pain processing in ﬁ  bromyalgia indicate that 
psychological stress (that is, depression, anxiety) and 
pain are processed somewhat independently in the 
central nervous system [7]. Supporting this conclusion 
are the clinical data indicating that drugs acting as both 
antidepressants and analgesics (for example, tricyclics or 
serotonin–norepinephrine reuptake inhibitors) are 
equally eﬀ  ective analgesics in chronic pain conditions in 
patients with and without depression [8]. Th  e lack of 
direct overlap in the central processing of stress and pain 
suggests that the degree to which stress inﬂ  uences pain, 
and vice versa, may be moderated by individual factors 
such as cognitions, coping/appraisal and social support 
[9,10].
In ﬁ  bromyalgia, as well as in autoimmune disorders, 
symptom expression is likely determined to a similar 
extent by genetic and environmental factors. Although 
there have been eﬀ   orts to link pain and subtle 
abnormalities in ANS and HPA system functioning seen 
in individuals with ﬁ  bromyalgia and other chronic pain 
syndromes, newer data suggest much more complex 
interrelationships between these systems. Observable 
changes in the ANS or HPA axis tone in some individuals 
may represent a baseline diathesis or risk factor for the 
subsequent development of chronic pain, or the changes 
may be due to pain itself or to the indirect eﬀ  ects of pain 
such as deconditioning secondary to decreased exercise.
In summary, when our patients say that stress worsens 
their disease, they may be correct. Although the study of 
stress is fraught with problems, there are clearly both 
immune mechanisms (that is, psychoneuroimmunology) 
and nonimmune mechanisms (for example, mechanisms 
operative in conditions such as ﬁ  bromyalgia, either alone 
or comorbid with autoimmune disorders) that may be 
responsible for increased disease activity and/or symp-
tom expression during periods of stress.
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